Xifaxan®
rifaximin 550 mg tablets

You are cordially invited to learn more about

Reducing the Burden of Cirrhosis and Hepatic Encephalopathy

Xifaxan® (rifaximin) 550 mg Tablets

PRESENTED BY

Apurva A. Modi, MD
Liver Consultants of Texas
Fort Worth, TX

October 23, 2018 at 6:30pm

Ranch Steakhouse

3000 W Britton Rd.
Oklahoma City, OK 73120
Phone: (405) 755-3501

Please RSVP on or before October 16, 2018 to Jordan Singleton at 817-875-5566 or Jordan.Singleton@Salix.com

This program is sponsored by Salix Pharmaceuticals. No CME/CE will be provided. Only physicians and health care professionals involved in providing patient care or product recommendations may attend this educational program. Attendance by guests or spouses is not permitted. Please note: Your name and the value of any meal/refreshment will be reported as required by federal and state laws. You must notify the Salix Pharmaceuticals representative upon sign-in if you maintain a license to practice medicine in Minnesota or Vermont.

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION

- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
- *Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued.

Please see additional Important Safety Information on next page and accompanying Full Prescribing Information for XIFAXAN.

Salix Pharmaceuticals

Xifaxan®
rifaximin 550 mg tablets

- There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
- Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
- In a clinical study, the most common adverse reactions for XIFAXAN in HE (≥10%) were peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%).
- INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
- XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying Full Prescribing Information for XIFAXAN.

Salix Pharmaceuticals